We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

VesCell™ Acknowledged as Best Available Commercial Treatment for no Option Cardiac Patients

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Stem cell research journal ‘Regenerative Medicine’ recently confirmed the achievements of TheraVitae Ltd. by naming the Israeli-Thai company as being a ‘serious player in the international arena of regenerative therapy’.

The bi-monthly journal, which provides a forum to address advances in stem cell research and regenerative medicine, makes the pronouncement in an article in the July 2006 issue.

Backed by the opinions of an International Editorial Board of over 65 experts, the periodical’s July round-up of industry news goes on to conclude that VesCell™, TheraVitae’s treatment for heart disease, provides the best commercially available stem cell-based treatment for ‘no-option’ cardiac patients.

These are patients afflicted by severe medical conditions that cannot be treated using conventional procedures such as bypass surgery or balloon angioplasty due to the risks associated with these options.

Patients are treated with self-derived stem cells isolated by TheraVitae’s proprietary technology. Angiogenic cell precursors harvested from the patients’ peripheral blood in Bangkok are expanded and differentiated in-vitro in a facility in Israel.

The product, VesCell™, is sent back to Thailand where is injected, either directly into patient’s heart, or delivered via intracoronary catheter.

Stressing that TheraVitae’s aim is not to seek a miracle cure for heart disease but to provide sufferers a new lease on life and the chance to once again enjoy activities which they never thought possible, Dr Valentin Fulga, CEO of TheraVitae is quoted, in Regenerative Medicine’s July 2006 issue, as saying, "Depending on the disease, we follow improvement in perfusion of the ischemic region in the heart in patients with angina pectoris, or ejection fraction for patients with heart failure."

"However, our cardinal assessment parameters remain the general condition of the patient and improvement in his/her ability to perform regular daily tasks."